Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targetsKartik Sehgal, Madhav V. Dhodapkar, Rituparna Das et al.|Blood|2015Cited by 133
Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker TrialJames Croft, Martin Kaiser, Sidra Ellis et al.|Blood|2019Cited by 4